

Philipp Erben

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6357592/philipp-erben-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

125
papers

4,529
citations

35
h-index

65
g-index

134
ext. papers

5,217
ext. citations

4.2
avg. IF

4.58
L-index

#	Paper	IF	Citations
125	Upper Tract Urinary Cancer Recurrence after Radical Cystectomy: Risk Assessment of Intraoperative Frozen Section.. <i>Urologia Internationalis</i> , 2022 , 1-9	1.9	
124	Baseline Modified Glasgow Prognostic Score (mGPS) Predicts Radiologic Response and Overall Survival in Metastatic Hormone-sensitive Prostate Cancer Treated With Docetaxel Chemotherapy.. <i>Anticancer Research</i> , 2022 , 42, 1911-1918	2.3	0
123	C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma.. <i>European Journal of Cancer</i> , 2022 , 167, 13-22	7.5	0
122	A comprehensive molecular characterization of the 8q22.2 region reveals the prognostic relevance of OSR2 mRNA in muscle invasive bladder cancer. <i>PLoS ONE</i> , 2021 , 16, e0248342	3.7	2
121	RNA Expression of DNA Damage Response Genes in Muscle-Invasive Bladder Cancer: Influence on Outcome and Response to Adjuvant Cisplatin-Based Chemotherapy. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
120	Neuropilin-2 and Its Transcript Variants Correlate with Clinical Outcome in Bladder Cancer. <i>Genes</i> , 2021 , 12,	4.2	1
119	Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients. <i>Cancers</i> , 2021 , 13,	6.6	1
118	The prognostic value of galactosylceramide-sulfotransferase (Gal3ST1) in human renal cell carcinoma. <i>Scientific Reports</i> , 2021 , 11, 10926	4.9	1
117	Factors to improve academic publishing success of physicians engaged in scientific research. <i>Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen</i> , 2021 , 162, 63-69	1.4	
116	POFUT1 mRNA expression as an independent prognostic parameter in muscle-invasive bladder cancer. <i>Translational Oncology</i> , 2021 , 14, 100900	4.9	5
115	High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 40, 63.e9-63.e9	2.8	1
114	The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer. <i>Cancer Management and Research</i> , 2021 , 13, 6567-6578	3.6	0
113	High IL-22RA1 gene expression is associated with poor outcome in muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 499.e1-499.e8	2.8	0
112	Phosphodiesterase Gene Expression as Independent Outcome Prediction Marker in Localized Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	2
111	Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy 2020 , 8,		18
110	Subtype specific expression and survival prediction of pivotal lncRNAs in muscle invasive bladder cancer. <i>Scientific Reports</i> , 2020 , 10, 20472	4.9	
109	Long noncoding RNA MIR31HG and its splice variants regulate proliferation and migration: prognostic implications for muscle invasive bladder cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020 , 39, 288	12.8	3

108	Clinical relevance of gene expression in localized and metastatic prostate cancer exemplified by FABP5. <i>World Journal of Urology</i> , 2020 , 38, 637-645	4	8
107	FOXA1 Gene Expression for Defining Molecular Subtypes of Muscle-Invasive Bladder Cancer after Radical Cystectomy. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	7
106	The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes. <i>Cancer Immunology Research</i> , 2019 , 7, 923-938	12.5	69
105	Radical cystectomy under continuous antiplatelet therapy with acetylsalicylic acid. <i>European Journal of Surgical Oncology</i> , 2019 , 45, 1260-1265	3.6	5
104	Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent Cohorts. <i>Translational Oncology</i> , 2019 , 12, 661-668	4.9	8
103	FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer. <i>BJU International</i> , 2019 , 123, 187-196	5.6	13
102	miR-10a-5p and miR-29b-3p as Extracellular Vesicle-Associated Prostate Cancer Detection Markers. <i>Cancers</i> , 2019 , 12,	6.6	28
101	and in Muscle Invasive Bladder Cancer: A Functional and Clinical Evaluation Based on In Silico and In Vitro Data. <i>Cancers</i> , 2019 , 11,	6.6	11
100	Programmed Death Ligand 1 (PD-L1) Status and Tumor-Infiltrating Lymphocytes in Hot Spots of Primary and Liver Metastases in Prostate Cancer With Neuroendocrine Differentiation. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 145-153.e5	3.3	10
99	Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. <i>European Journal of Cancer</i> , 2019 , 106, 234-243	7.5	39
98	Analysis of the prognostic relevance of sex-steroid hormonal receptor mRNA expression in muscle-invasive urothelial carcinoma of the urinary bladder. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019 , 474, 209-217	5.1	7
97	High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 248-256.e2	3.3	8
96	Prognostic Value of Molecular Breast Cancer Subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in Muscle Invasive Bladder Cancer. <i>Translational Oncology</i> , 2018 , 11, 467-476	4.9	11
95	Complete and Durable Remission of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Urothelial Carcinoma Following Third-Line Treatment with Trastuzumab and Gemcitabine. <i>Urologia Internationalis</i> , 2018 , 100, 122-125	1.9	7
94	FOXM1 predicts disease progression in non-muscle invasive bladder cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018 , 144, 1701-1709	4.9	10
93	Decreased Invasion of Urothelial Carcinoma of the Bladder by Inhibition of Matrix-Metalloproteinase 7. <i>Bladder Cancer</i> , 2018 , 4, 67-75	1	6
92	High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients. <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 403-412	7.4	39
91	Subclassification, survival prediction and drug target analyses of chemotherapy-naïve muscle-invasive bladder cancer with a molecular screening. <i>Oncotarget</i> , 2018 , 9, 25935-25945	3.3	16

90	A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy. <i>Oncotarget</i> , 2018 , 9, 15001-15014	3.3	22
89	Predictive value of lymphangiogenesis and proliferation markers on mRNA level in urothelial carcinoma of the bladder after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 530.e19-530.e27	2.8	4
88	CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making. <i>Scientific Reports</i> , 2018 , 8, 14383	4.9	16
87	Cell-Free DNA and Neuromediators in Detecting Aggressive Variant Prostate Cancer. <i>Oncology Research and Treatment</i> , 2018 , 41, 627-633	2.8	2
86	mRNA-Expression of and Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological Variants. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	24
85	In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017 , 470, 267-274	5.1	36
84	RAB27A, RAB27B and VPS36 are downregulated in advanced prostate cancer and show functional relevance in prostate cancer cells. <i>International Journal of Oncology</i> , 2017 , 50, 920-932	4.4	23
83	Database-augmented Mass Spectrometry Analysis of Exosomes Identifies Claudin 3 as a Putative Prostate Cancer Biomarker. <i>Molecular and Cellular Proteomics</i> , 2017 , 16, 998-1008	7.6	42
82	High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer. <i>Translational Oncology</i> , 2017 , 10, 340-345	4.9	17
81	Novel insights into a reputedly irreversible process: combined mRNA and miRNA profiling of tissue from vesicourethral anastomotic stenosis after radical prostatectomy. <i>World Journal of Urology</i> , 2017 , 35, 1701-1711	4	3
80	ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ. <i>Urologia Internationalis</i> , 2017 , 98, 282-289	1.9	22
79	The EEF1A2 gene expression as risk predictor in localized prostate cancer. <i>BMC Urology</i> , 2017 , 17, 86	2.2	11
78	Impact of Altered WNT2B Expression on Bladder Wall Fibroblasts: Implications for Apoptosis Regulation in the Stroma of the Lower Urinary Tract. <i>Urologia Internationalis</i> , 2017 , 99, 476-483	1.9	1
77	FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes. <i>Oncotarget</i> , 2017 , 8, 47595-47606	3.3	14
76	Predictive value of molecular subtyping in NMIBC by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from formalin fixed TUR biopsies. <i>Oncotarget</i> , 2017 , 8, 67684-67695	3.3	11
75	ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade of non-muscle-invasive bladder carcinoma (NMIBC). <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016 , 469, 547-552	5.1	20
74	Lapatinib-induced mesenchymal-epithelial transition in squamous cell carcinoma cells correlates with unexpected alteration of E-catenin expression. <i>Oncology Letters</i> , 2016 , 11, 2715-2724	2.6	5
73	Subclassification and outcome prediction of patients with muscle invasive urothelial carcinoma (MIUC) treated by radical cystectomy (RC) with a NanoString based molecular screening.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4525-4525	2.2	1

72	Expression of the p53 Inhibitors MDM2 and MDM4 as Outcome Predictor in Muscle-invasive Bladder Cancer. <i>Anticancer Research</i> , 2016 , 36, 5205-5213	2.3	11
71	Prognostic Impact of mRNA Expression Levels of HER1-4 (ERBB1-4) in Patients with Locally Advanced Rectal Cancer. <i>Gastroenterology Research and Practice</i> , 2016 , 2016, 3481578	2	2
70	MMP9, Cyclin D1 and E-catenin Are Useful Markers of p16-positive Squamous Cell Carcinoma in Therapeutic EGFR Inhibition In Vitro. <i>Anticancer Research</i> , 2015 , 35, 3801-10	2.3	2
69	Expression of transketolase-like gene 1 (TKTL1) depends on disease phase in patients with chronic myeloid leukaemia (CML). <i>Journal of Cancer Research and Clinical Oncology</i> , 2014 , 140, 411-7	4.9	2
68	Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. <i>Leukemia</i> , 2014 , 28, 1988-92	10.7	98
67	The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. <i>Annals of Hematology</i> , 2014 , 93, 81-8	3	113
66	Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014 , 140, 1965-9	4.9	20
65	MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure. <i>Leukemia</i> , 2014 , 28, 1478-85	10.7	17
64	The FIP1L1-PDGFRB fusion gene and the KIT D816V mutation are coexisting in a small subset of myeloid/lymphoid neoplasms with eosinophilia. <i>Blood</i> , 2014 , 123, 595-7	2.2	14
63	IL1RN and KRT13 Expression in Bladder Cancer: Association with Pathologic Characteristics and Smoking Status. <i>Advances in Urology</i> , 2014 , 2014, 184602	1.6	7
62	Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. <i>Haematologica</i> , 2014 , 99, 1441-7	6.6	73
61	Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms. <i>Genes Chromosomes and Cancer</i> , 2014 , 53, 411-21	5	20
60	Microvascular invasion of testicular nonseminomatous germ cell tumors: implications of separate evaluation of lymphatic and blood vessels. <i>Journal of Urology</i> , 2014 , 192, 593-9	2.5	9
59	Prognostic value of HER2 expression in patients with bladder cancer treated with radical cystectomy: A biomarker study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15515-e15515	2.2	1
58	Incomplete epithelial-mesenchymal transition in p16-positive squamous cell carcinoma cells correlates with E-catenin expression. <i>Anticancer Research</i> , 2014 , 34, 7061-9	2.3	14
57	Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib. <i>Annals of Hematology</i> , 2013 , 92, 1345-50	3	39
56	Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study. <i>Annals of Hematology</i> , 2013 , 92, 907-15	3	1
55	Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group. <i>Annals of Hematology</i> , 2013 , 92, 41-52	3	43

54	Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013 , 139, 1985-93	4.9	9
53	Comprehensive mutational profiling in advanced systemic mastocytosis. <i>Blood</i> , 2013 , 122, 2460-6	2.2	183
52	Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012 , 138, 2034-9	4.9	6
51	Activating CBL mutations are associated with a distinct MDS/MPN phenotype. <i>Annals of Hematology</i> , 2012 , 91, 1713-20	3	26
50	Molecular analysis of desmoid tumors with a high-density single-nucleotide polymorphism array identifies new molecular candidate lesions. <i>Oncology Research and Treatment</i> , 2012 , 35, 684-9	2.8	1
49	HERV-E-mediated modulation of PLA2G4A transcription in urothelial carcinoma. <i>PLoS ONE</i> , 2012 , 7, e49341	3.7	23
48	Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common β subunit c of cytokine receptors. <i>Leukemia</i> , 2012 , 26, 1321-8	10.7	7
47	Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). <i>Leukemia</i> , 2012 , 26, 2096-102	10.7	328
46	SNP array analysis of acute promyelocytic leukemia may be of prognostic relevance and identifies a potential high risk group with recurrent deletions on chromosomal subband 1q31.3. <i>Genes Chromosomes and Cancer</i> , 2012 , 51, 756-67	5	15
45	Chemotherapeutic alteration of Eatenin and c-kit expression by imatinib in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro. <i>Oncology Reports</i> , 2012 , 27, 270-80	3.5	4
44	Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFR α positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. <i>Leukemia</i> , 2012 , 26, 162-4	10.7	49
43	Alteration of MMP-2 and -14 expression by imatinib in HPV-positive and -negative squamous cell carcinoma. <i>Oncology Reports</i> , 2012 , 28, 172-8	3.5	3
42	KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011 , 81, 1032-8	4	45
41	Novel imatinib-sensitive PDGFR α -activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. <i>Blood</i> , 2011 , 117, 2935-43	2.2	67
40	Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. <i>Blood</i> , 2011 , 118, 2239-42	2.2	61
39	Synergistic effects of imatinib and carboplatin on VEGF, PDGF and PDGFR α expression in squamous cell carcinoma of the head and neck in vitro. <i>International Journal of Oncology</i> , 2011 , 38, 1001-4	4.4	8
38	Down-regulation of MMP-2 expression due to inhibition of receptor tyrosine kinases by imatinib and carboplatin in HNSCC. <i>Oncology Reports</i> , 2011 , 25, 1145-51	3.5	6
37	Chemotherapeutic alteration of VEGF-/PDGF- and PDGFR α expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro. <i>Oncology Reports</i> , 2011 , 26, 1099-109	3.5	5

36	The role of zinc protoporphyrin measurement in the differentiation between primary myelofibrosis and essential thrombocythaemia. <i>Annals of Hematology</i> , 2011 , 90, 389-94	3	1
35	Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy. <i>BMC Cancer</i> , 2011 , 11, 363	4.8	33
34	Front Line Treatment of Elderly Patients with Acute Promyelocytic Leukemia: Long-Term Results of the German AML Cooperative Group. <i>Blood</i> , 2011 , 118, 425-425	2.2	
33	Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1429-35	2.2	129
32	Neue Entwicklungen in der perioperativen (Radio-)Chemotherapie des lokal fortgeschrittenen Rektumkarzinoms. <i>Deutsche Zeitschrift Fur Onkologie</i> , 2010 , 42, 52-59	0.3	
31	Annexin and survivin in locally advanced rectal cancer: indicators of resistance to preoperative chemoradiotherapy?. <i>Onkologie</i> , 2010 , 33, 439-44		7
30	TFG, a target of chromosome translocations in lymphoma and soft tissue tumors, fuses to GPR128 in healthy individuals. <i>Haematologica</i> , 2010 , 95, 20-6	6.6	45
29	Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. <i>Haematologica</i> , 2010 , 95, 738-44	6.6	60
28	Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. <i>Cancer</i> , 2010 , 116, 3852-61	6.4	96
27	High Density SNP Array Analysis of Acute Promyelocytic Leukemia (APL) Detects New Common Genomic Copy Number Alterations as Possible Cooperating Lesions. <i>Blood</i> , 2010 , 116, 2721-2721	2.2	
26	Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3472-9	2.2	154
25	Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4204-10	2.2	248
24	Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2). <i>Genes Chromosomes and Cancer</i> , 2009 , 48, 179-83	5	33
23	The molecular anatomy of the FIP1L1-PDGFRB fusion gene. <i>Leukemia</i> , 2009 , 23, 271-8	10.7	16
22	Harmonization of molecular monitoring of CML therapy in Europe. <i>Leukemia</i> , 2009 , 23, 1957-63	10.7	170
21	Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009 , 74, 1487-93	4	91
20	Cause and management of therapy resistance. <i>Best Practice and Research in Clinical Haematology</i> , 2009 , 22, 367-79	4.2	16
19	Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer. <i>Anti-Cancer Drugs</i> , 2009 , 20, 519-24	2.4	29

18	Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. <i>Blood</i> , 2009 , 114, 4944-53	2.2	230
17	Interferon Alpha 2a (IFN) Maintenance Therapy After Imatinib Plus IFN Induction Therapy in Chronic Myeloid Leukemia (CML) Induces Stable Long-Term Molecular Remissions and Is Associated with Increased Proteinase 3 (PR3) Expression and the Presence of PR1-Specific T-Cells.. <i>Blood</i> , 2009 , 114, 647-647	2.2	1
16	Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. <i>Leukemia</i> , 2008 , 22, 96-102	10.7	87
15	Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. <i>British Journal of Haematology</i> , 2008 , 143, 707-15	4.5	104
14	Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. <i>Haematologica</i> , 2008 , 93, 186-92	6.6	87
13	Suitability of the PAXgene system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008 , 46, 318-22	5.9	6
12	ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. <i>Haematologica</i> , 2008 , 93, 1389-93	6.6	43
11	Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib. <i>Haematologica</i> , 2008 , 93, 765-9	6.6	35
10	mRNA expression of platelet-derived growth factor receptor-beta and C-KIT: correlation with pathologic response to cetuximab-based chemoradiotherapy in patients with rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 72, 1544-50	4	15
9	Nilotinib Efficacy According to Baseline BCR-ABL Mutations in Patients with Imatinib-Resistant Chronic Myeloid Leukemia in Chronic Phase (CML-CP). <i>Blood</i> , 2008 , 112, 3216-3216	2.2	8
8	Molecular Response to First Line Imatinib Therapy Is Predictive for Long Term Event Free Survival in Patients with Chronic Phase Chronic Myelogenous Leukemia [An Interim Analysis of the Randomized German CML Study IV. <i>Blood</i> , 2008 , 112, 333-333	2.2	8
7	Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses. <i>Archives of Dermatology</i> , 2007 , 143, 736-40		59
6	Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. <i>Blood</i> , 2007 , 109, 2147-55	2.2	125
5	Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFR α -positive chronic eosinophilic leukemia. <i>Blood</i> , 2007 , 109, 4635-40	2.2	167
4	JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. <i>Lancet Oncology</i> , 2007 , 8, 658-60	21.7	61
3	Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. <i>Blood</i> , 2007 , 109, 3207-13	2.2	354
2	Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFR α fusion gene. <i>Genes Chromosomes and Cancer</i> , 2006 , 45, 950-6	5	58
1	Prostate cancer transfection by acoustic energy using pEGFP-N1 as reporter gene in the solid Dunning R-3327-MatLu tumor. <i>Prostate Cancer and Prostatic Diseases</i> , 2003 , 6, 290-3	6.2	3

